Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking indication extension for TECVAYLI (teclistamab) as monotherapy for relapsed/refractory multiple myeloma (RRMM) patients who have received at least one prior therapy. The filing, supported by Phase III MajesTEC-9 trial data showing 71% reduction in disease progression risk and 40% reduction in death risk versus standard of care, positions the BCMA/CD3 bispecific for second-line use in a heavily pre-treated, refractory population.
Regulatory Submission Overview
Element
Detail
Agency
European Medicines Agency (EMA)
Application Type
Type II variation (indication extension)
Product
TECVAYLI (teclistamab)
Requested Indication
Monotherapy for RRMM after ≥1 prior therapy (second-line expansion)
Current EU Approval
RRMM after ≥3 prior therapies (August 2022) – fourth-line setting
Redirects patient T-cells to target and eliminate BCMA-expressing myeloma cells
Administration
Subcutaneous injection (no CAR-T manufacturing required)
Current EU Label
Fourth-line+ (≥3 prior therapies including IMiD, PI, anti-CD38)
U.S. Status
Approved (similar fourth-line indication); second-line combo approval March 2026
Strategic Context & Market Impact
Factor
Implication
Line of Therapy Expansion
Moves from fourth-line to second-line – 3x addressable patient population increase in EU
Competitive Positioning
Challenges CAR-T therapies (cilta-cel, ide-cel) in earlier relapse; convenience advantage (off-the-shelf vs. manufacturing)
MajesTEC Program
MajesTEC-9 supports monotherapy; MajesTEC-3 (combo with daratumumab) approved U.S. March 2026
Revenue Forecast
Analysts project €3-5 billion peak EU sales with second-line expansion; accelerates trajectory vs. CAR-T competition
Safety Consistency
Manageable profile supports earlier-line use where patients have better performance status
Competitive Landscape
Competitor
Product
Mechanism
EU Line Setting
TECVAYLI Differentiation
BMS/Janssen
Abecma (ide-cel)
Anti-BCMA CAR-T
Second-line approved
Off-the-shelf convenience; no lymphodepletion
J&J/Legend
Carvykti (cilta-cel)
Anti-BCMA CAR-T
Second-line approved
Subcutaneous vs. IV infusion; broader site availability
Sanofi
Sarclisa (isatuximab)
Anti-CD38 mAb
Second-line (combo)
Bispecific T-cell engagement vs. mAb-mediated killing
J&J
TECVAYLI
BCMA/CD3 bispecific
Fourth-line (current); second-line (pending)
First bispecific with second-line monotherapy data
Regulatory Timeline & Launch Outlook
Milestone
Timeline
Status
EMA Review
2026-2027
Type II variation assessment; CHMP opinion anticipated Q4 2026
EU Approval
Q1-Q2 2027
Conditional or full marketing authorization
Commercial Launch
Q2-Q3 2027
Hospital formulary access; myeloma center education
Reimbursement
2027-2028
HTA negotiations (NICE, IQWiG, etc.)
Forward‑Looking Statements This brief contains forward‑looking statements regarding EMA review timelines, indication expansion, and competitive positioning for TECVAYLI in second-line multiple myeloma. Actual results may differ due to regulatory decisions, HTA negotiations, and competitive dynamics with CAR-T therapies.-Fineline Info & Tech
By Fineline Cube 